TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00885820
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00885820
Drug: Corticosteroids (Prednisone)
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT03355482
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160mg IM at baseline
Study: NCT03996369
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study: NCT00338182
Drug: AZD1152 part A
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-hour continuous intravenous infusion
Study: NCT00338182
Drug: AZD1152 part B
Normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-hour intravenous infusion
Study: NCT04308031
Drug: Ivabradine 5 mg [Corlanor]
Normalized name: ivabradine 5 MG [Corlanor]
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
Study: NCT04308031
Drug: Digoxin 0.25 mg
Normalized name: digoxin 0.25 MG
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
Study: NCT01432600
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Study: NCT01432600
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Study: NCT00957125
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
Study: NCT00957125
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
Study: NCT00957125
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
Study: NCT02710162
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study: NCT01542879
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03799094
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravenous vitamin C therapy at the indicated dose.
Study: NCT01467401
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Study: NCT01467401
Drug: biphasic human insulin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Study: NCT03888092
Drug: Z650
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study: NCT04485013
Drug: TTX-080
Normalized name: TTX-siPDL1
DrugBank: TTX-siPDL1 (DB18550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dose (Q3W)
Study: NCT04485013
Drug: TTX-080
Normalized name: TTX-siPDL1
DrugBank: TTX-siPDL1 (DB18550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose (Q3W)
Study: NCT01063439
Drug: Busulfan, Etoposide, Cytarabine, Melphalan
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
Study: NCT04485013
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose (Q3W)
Study: NCT04485013
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT04485013
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose (Q2W)
Study: NCT04485013
Drug: TTX-080
Normalized name: TTX-siPDL1
DrugBank: TTX-siPDL1 (DB18550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose (Q2W)
Study: NCT03891979
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29.
Study: NCT03891979
Drug: Ciprofloxacin 500mg PO BID days 1-29
Normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics will continue throughout the entire four week pre-operative period.
Study: NCT03891979
Drug: Metronidazole 500mg PO TID days 1-29
Normalized name: metronidazole 500 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics will continue throughout the entire four week pre-operative period.
Study: NCT04296799
Drug: SMP-100
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD/MAD
Study: NCT00686634
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg by mouth once daily
Study: NCT02802137
Drug: tafluprost
Normalized name: Tafluprost
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02802137
Drug: tafluprost and dorzolamide/timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03852407
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
Study: NCT03852407
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/m² on day -2
Study: NCT03852407
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m² on days -6, -5, -4, -3, and -2
Study: NCT03852407
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg on days +3 and +4.
Study: NCT03271983
Drug: Metronidazole gel 1
Normalized name: metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RLD gel
Study: NCT03271983
Drug: Metronidazole gel 2
Normalized name: Metronidazole Vaginal Gel
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: generic gel
Study: NCT03271983
Drug: Metronidazole cream
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: generic cream
Study: NCT04556656
Drug: Pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine hard gelatin capsule
Study: NCT02402725
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
Study: NCT04541706
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
Study: NCT02282345
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01213576
Drug: Albendazole 400mg and ivermectin 200mcg/kg
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally given annually
Study: NCT01213576
Drug: Albendazole and ivermectin
Normalized name: Albendazole and ivermectin only product
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole 800 mg and ivermectin 400mg orally given annually
Study: NCT01213576
Drug: Albendazole 400mg and ivermectin 200mcg/kg
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400mg and ivermectin 200mcg/kg given twice a year
Study: NCT01213576
Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole 800mg and ivermectin 400mcg/kg given twice a year
Study: NCT00023699
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00088556
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6 mg/mL/min Once every 3 weeks
Study: NCT00088556
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m² Once every 3 weeks
Study: NCT02310009
Drug: Anakinra (AN)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02983097
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m²
Study: NCT02983097
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatinum 100 mg / m²
Study: NCT02983097
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatinum AUC5
Study: NCT02983097
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg
Study: NCT02983097
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 2000 mg/m², administered twice
Study: NCT02983097
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-20 mg administered either d1-d7, or d-6-d7
Study: NCT02983097
Drug: PegFilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PegFilgrastim 6 mg
Study: NCT00595374
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00595374
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00400296
Drug: RG547
Normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
Study: NCT05088239
Drug: prophylactic antibiotics duration
Normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
Study: NCT01704612
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
Study: NCT00520585
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
Study: NCT02296138
Drug: olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed dose combination
Study: NCT02296138
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dose combination
Study: NCT02296138
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03364530
Drug: Gemcitabine-Oxaliplatin Regimen
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity.
Study: NCT01431209
Drug: Ruxolitinib Phosphate
Normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03328273
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
Study: NCT03328273
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
Study: NCT01506063
Drug: Levocetirizine DiHCl
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine DiHCl Tablets 5 mg
Study: NCT01838863
Drug: Crystalloid fluid (standard of care for resuscitation)
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
Study: NCT04300920
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
Study: NCT03020030
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
Study: NCT03020030
Drug: Erwinia asparaginase
Normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only for patients with Pegaspargase allergy or silent inactivation.
Study: NCT01940978
Drug: Methylphenidate ER
Normalized name: Methylphenidate Hydrochloride 20 MG Oral Tablet, Extended Release [METHYLPHENIDATE ER]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Watson generic, starting dose 18mg QD
Study: NCT01940978
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cyproheptadine hydrochloride
Study: NCT03020030
Drug: CYTARABINE
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care
Study: NCT00468312
Drug: Mometasone furoate nasal spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
Study: NCT04233918
Drug: Evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part A: Single IV dose Part B \& C: IV dose Q4W
Study: NCT01937104
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60
Study: NCT03020030
Drug: DASATINIB
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of Care
Study: NCT03020030
Drug: DEXAMETHASONE
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care
Study: NCT03020030
Drug: Dexrazoxane
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT03020030
Drug: ETOPOSIDE
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of Care
Study: NCT03020030
Drug: NELARABINE
Normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT03020030
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT04083976
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive erdafitinib oral tablets.
Study: NCT03289910
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03289910
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03289910
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03289910
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01502917
Drug: Radioactive iodine-labeled monoclonal antibody omburtamab
Normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
Study: NCT02795949
Drug: Antipseudomonal beta-lactam antibiotic
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion
Study: NCT04201418
Drug: Patisiran
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patisiran-lipid complex injection, for intravenous use
Study: NCT00431236
Drug: Oral Casopitant (GW679769)
Normalized name: maropitant Oral Tablet
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00431236
Drug: IV Casopitant (GW679769)
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00431236
Drug: IV ondansetron hydrochloride
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00431236
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01052038
Drug: Dexamethasone 0.05mg/kr administration
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
Study: NCT01052038
Drug: Dexamethasone 0.1mg/kg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
Study: NCT00409175
Drug: Fx-1006A
Normalized name: Fx-1006A
DrugBank: Fx-1006A (DB05352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Study: NCT00430183
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
Study: NCT00703703
Drug: Darifenacin
Normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin tablets 15 mg once daily
Study: NCT00703703
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine extended release (ER) 4 mg once daily
Study: NCT03986073
Drug: TQ-F3083 capsule 10 mg
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.